26th Jul 2016 09:35
LONDON (Alliance News) - Niche pharmaceuticals firm Quantum Pharma PLC on Tuesday said its Colonis unit has launched its Mucodis Rectal Gel.
The gel is designed to prevent rectal mucositis, a common side effect of chemotherapy and radiotherapy in cancer patients.
"We are excited by the potential that the Mucodis range offers the NHS and patients as there is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving patients' quality of life," said Andrew Scaife, Quantum's chief executive.
Quantum shares were down 1.8% to 64.30 pence Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.